DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) ended the recent trading session at $137.84, demonstrating a +1.26% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.94%. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 1.52%.
Coming into today, shares of the kidney dialysis provider had lost 6.39% in the past month. In that same time, the Medical sector gained 4.95%, while the S&P 500 gained 1.67%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. It is anticipated that the company will report an EPS of $2.7, marking a 4.25% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $3.3 billion, showing a 3.5% escalation compared to the year-ago quarter.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $10.76 per share and revenue of $13.48 billion. These results would represent year-over-year changes of +11.16% and +5.15%, respectively.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, DaVita HealthCare boasts a Zacks Rank of #3 (Hold).
Investors should also note DaVita HealthCare's current valuation metrics, including its Forward P/E ratio of 12.66. This signifies a discount in comparison to the average Forward P/E of 20.85 for its industry.
Investors should also note that DVA has a PEG ratio of 0.94 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.93 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 71, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DaVita Inc. (DVA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Hundreds of people raise $84,000 for Pulmonary Fibrosis Foundation during annual walk in Pittsburgh
Hundreds of people gathered in Pittsburgh's Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation's annual walk. Participants walked on a one or two-mile course in support of those living with pulmonary fibrosis, a group of progressive lung diseases that cause scarring in the lungs, which limits oxygen intake necessary for major organs to function. Pulmonary fibrosis currently affects more than 250,000 Americans, and 50,000 new cases are diagnosed each year, according to PFF. Organizers say individuals and teams from the Pittsburgh region raised more than $84,000 to advance research for a cure for the life-threatening disease. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Bloomberg
32 minutes ago
- Bloomberg
Fed's Daly Says Central Bank Communication Should Be Flexible
Federal Reserve Bank of San Francisco President Mary Daly said central bankers need to communicate with flexibility at times of uncertainty, given that using strong forward guidance sometimes 'comes with a price.' 'The economy is dynamic, and our communications must match it,' Daly said Sunday in a speech prepared for the Western Economic Association International's 100th Annual Conference. Daly didn't comment on the outlook for the economy or policy in her written remarks, which she also said were not about the Fed's ongoing framework review.
Yahoo
37 minutes ago
- Yahoo
AppLovin (NasdaqGS:APP) Reports Robust Q1 Earnings Despite Price Dip Over Last Quarter
AppLovin reported robust Q1 earnings with sales growth and improved net income, yet it faced a 4% share price decline over the last quarter. The price move contrasts with the broader market's flat performance but can be partly attributed to the substantial goodwill impairment and the securities class action lawsuit filed against the company. Despite these challenges, the ongoing share repurchase program and strategic advancements like Chartboost's new capabilities on the MAX platform may have cushioned the impact. Meanwhile, impending board changes and M&A discussions could introduce new dynamics for the company's future trajectory. AppLovin has 3 warning signs we think you should know about. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent developments surrounding AppLovin, including the goodwill impairment and class action lawsuit, may introduce uncertainties that weigh on investor sentiment. While these challenges could pressure the company's revenue and earnings forecasts in the short term, the ongoing share repurchase program and strategic investments in AI and global advertising might support long-term growth trajectories. Over a three-year period, AppLovin's total shareholder return was very large, showcasing its resilience and potential for significant value creation. Despite a recent 4% share price decline, the company's one-year performance exceeded the US Software industry's 16.8% return, indicating robust comparative growth. With a current share price of US$304.62 and analysts' price target of US$432.90, the stock remains at a substantial discount, suggesting potential for future appreciation if the company meets earnings projections. Gain insights into AppLovin's historical outcomes by reviewing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:APP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
